Trials / Recruiting
RecruitingNCT06259162
LAG3 Expression in Triple Negative Breast Cancer
The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Accepted
Summary
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | LAG-3 expression / immune checkpoint protein expression | Evaluate the tissue and blood before and after chemotherapy |
Timeline
- Start date
- 2022-11-18
- Primary completion
- 2025-07-01
- Completion
- 2027-12-31
- First posted
- 2024-02-14
- Last updated
- 2024-02-14
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06259162. Inclusion in this directory is not an endorsement.